链激酶

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 链激酶
• 中文别名: 链球菌肽酶A.；链球菌纤溶酶；溶栓酶
• 英文名称: 4-cyclohexylpyrrolidin-1-ium-2-carboxylate
• 化学式: C11H19NO2
• 分子量: 197.27
• InChiKey: XRZWVSXEDRYQGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
  申请人：PETZELBAUER Peter

  公开号：US20100081787A1

  公开（公告）日：2010-04-01

  Peptides, peptidomimetics and derivatives thereof of the general formula I: H 2 N-GHRPX 1 - β -X 4 X 5 X 6 X 7 X 8 X 9 X 10 -X 11 (I), in which X 1 -X 10 denote one of the 20 genetically coded amino acids, wherein X 8 , X 9 and X 10 may also denote a single chemical bond; X 11 denotes OR 1 in which R 1 equals hydrogen or (C 1 -C 10 ) alkyl NR 2 R 3 with R 2 and R 3 are equal or different and denote hydrogen, (C 1 -C 10 ) alkyl, or a residue —W-PEG 5-60K , in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG 5-60K , in which Y denotes a chemical bond or a genetically coded amino acids from the group S, C, K or R and Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, and their physiologically acceptable salts, and β denotes an amino acid, or a peptidomimetic element, which induces a bend or turn in the peptide backbone.

  通用公式I：H2N-GHRPX1-β-X4X5X6X7X8X9X10-X11(I)中的肽、肽类似物和衍生物，其中X1-X10表示20种遗传编码的氨基酸之一，其中X8、X9和X10也可以表示单一化学键；X11表示OR1，其中R1等于氢或(C1-C10)烷基NR2R3，其中R2和R3相同或不同，表示氢、(C1-C10)烷基，或者残基—W-PEG5-60K，其中PEG残基通过适当的间隔物W连接到N-原子，或者残基NH—Y-Z-PEG5-60K，其中Y表示化学键或来自S、C、K或R组的遗传编码氨基酸，Z表示间隔物，通过该间隔物可以连接聚乙二醇（PEG）残基，并且它们的生理上可接受的盐，β表示氨基酸或诱导肽骨架中弯曲或转弯的肽类或肽类似元素。
• [EN] CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS<br/>[FR] CONJUGUÉS POUR UNE RÉACTIVITÉ SÉLECTIVE À DES DIOLS VICINAUX
  申请人：PROTOMER TECH INC

  公开号：WO2021202802A1

  公开（公告）日：2021-10-07

  Embodiments of the present disclosure relate to sensors that can selectively bind to specific vicinal diols in the presence of other diols. These boronated vicinal diol-responsive sensor compounds can sense levels of specific vicinal diols and respond to these molecules in the body. In certain embodiments, the vicinal diol is a cis diol, for example, a hexose such as glucose. In certain embodiments the sensors are conjugated to a drug substance, and the sensors may change the biophysical characteristics, pharmacokinetics, and/or activity of the drug substance in response to the vicinal diol. The drug substance may be or include a polypeptide, such as an insulin, a human endocrine or incretin peptide, or an analogue thereof, and may contain one or more modified amino acids containing a vicinal diol-responsive sensor.

  本公开的实施例涉及传感器，该传感器可以在其他二醇存在的情况下选择性地结合特定的邻二醇。这些硼化邻二醇响应传感器化合物可以感知特定邻二醇的水平，并对这些分子在体内做出反应。在某些实施例中，邻二醇是顺式二醇，例如六糖，如葡萄糖。在某些实施例中，传感器与药物物质结合，传感器可以改变药物物质的生物物理特性，药代动力学和/或活性，以响应邻二醇。药物物质可以是或包括多肽，例如胰岛素，人类内分泌或肠促素肽或其类似物，并且可能包含一个或多个含有邻二醇响应传感器的修饰氨基酸。
• Process for manufacture of fosinopril sodium
  申请人：——

  公开号：US20040225127A1

  公开（公告）日：2004-11-11

  The present invention discloses a process for the synthesis of fosinopril as a single desired isomer of high purity in two steps comprising of (a) preparation of fosinopril as a mixture of four diastereomers and (b) separation of the desired isomer from the mixture through formation of alkali metal salts followed by crystallisation.

  本发明披露了一种合成高纯度单一所需异构体的福辛普利的方法，包括两个步骤：(a)制备福辛普利的四个对映异构体的混合物和(b)通过形成碱金属盐并结晶分离所需的异构体。
• HIV protease inhibitors
  申请人：JAPAN ENERGY CORPORATION

  公开号：EP0490667A2

  公开（公告）日：1992-06-17

  Human immunodeficiency virus (HIV) protease inhibitors comprising a compound represented by the following general formula or pharmaceutically acceptable salt thereof: The inhibitors are effective for treating a patient suffering from AIDS and AIDS related diseases.

  人类免疫缺陷病毒（HIV）蛋白酶抑制剂，包括由以下通式代表的化合物或其药学上可接受的盐： 这些抑制剂可有效治疗艾滋病和艾滋病相关疾病患者。
• BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP3912679A1

  公开（公告）日：2021-11-24

  The invention is based on the fibrin-derived peptides as therapeutic compounds for the treatment of inflammatory complications of virally caused diseases, such as a diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of certain fibrin derived peptides and analogues of these compounds resulted in a surprisingly effective patient recovery.

  本发明基于纤维蛋白衍生肽作为治疗化合物，用于治疗病毒引起的疾病的炎症并发症，如内皮细胞弥漫性炎症，也称为系统性内皮细胞炎或血管炎及相关疾病。使用某些纤维蛋白衍生肽和这些化合物的类似物后，病人的康复效果令人惊讶。